Preclinical evaluation of uPAR-ICG-FVIOs for dual-mode imaging and magnetic hyperthermia therapy in pancreatic cancer
This study presents the first theranostic applications of u-I-FVIOs, highlighting their potential as a dual-mode imaging and targeted MHT agent for pancreatic cancer.
Authors
- Chong Wu (ORCID: https://orcid.org/0000-0002-0818-0312)
- Kan Zhang (ORCID: https://orcid.org/0000-0003-1121-3426)
- Haojie Yang (ORCID: https://orcid.org/0000-0003-0476-3286)
- Fen Jiang (ORCID: https://orcid.org/0000-0002-3143-9265)
- Xiaolong Wu (ORCID: https://orcid.org/0000-0002-4064-7840)
- Tao Luo (ORCID: https://orcid.org/0000-0002-9417-7645)
- Zhigang Chen
Institutions
- Inje University (KR)
- Central South University (CN)
- The First People's Hospital of Changde (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fphar.2025.1681718
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00